非诺贝特对空腹血糖受损和糖耐量受损患者淋巴细胞细胞因子释放的影响：初步报告。
The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.
机构信息
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland.
出版信息
Atherosclerosis. 2010 Nov;213(1):325-8. doi: 10.1016/j.atherosclerosis.2010.07.016. Epub 2010 Jul 22.
OBJECTIVE
The aim of our study was to investigate the effect of fenofibrate on lymphocyte secretory function in patients with isolated early glucose metabolism abnormalities.
METHODS
Fifty-eight patients with impaired fasting glucose (IFG), fifty-six subjects with impaired glucose tolerance (IGT) and fifty-five normolipidemic control subjects with asymptomatic atherosclerosis, were treated for 90 days with either micronized fenofibrate (200 mg/day) or placebo.
RESULTS
Compared to control subjects, lymphocytes of both IGF and IGT patients released more amounts of interleukin-2, interferon-γ and TNF-α, and exhibited higher plasma levels of hsCRP. Despite improving glucose metabolism markers in both IFG and IGT subjects, fenofibrate reduced lymphocyte cytokine release only in the latter group of patients.
CONCLUSIONS
Our results show for the first time that lymphocyte secretory function is disturbed at early stages of glucose metabolism disturbances and that IGT- but not IFG-induced abnormal function of T cells is corrected by fenofibrate administration.
目的
本研究旨在探讨非诺贝特对单纯早期糖代谢异常患者淋巴细胞分泌功能的影响。
方法
58 例空腹血糖受损（IFG）患者、56 例糖耐量受损（IGT）患者和 55 例无症状动脉粥样硬化且血脂正常的对照受试者接受为期 90 天的治疗，分别给予微粒化非诺贝特（200mg/天）或安慰剂。
结果
与对照组相比，IFG 和 IGT 患者的淋巴细胞释放出更多的白细胞介素-2、干扰素-γ和 TNF-α，且 hsCRP 血浆水平更高。尽管非诺贝特改善了 IFG 和 IGT 患者的糖代谢标志物，但仅在后者组患者中降低了淋巴细胞细胞因子的释放。
结论
我们的研究结果首次表明，在糖代谢紊乱的早期阶段，淋巴细胞的分泌功能就已经受到了干扰，而非诺贝特治疗可以纠正 IGT 而非 IFG 引起的 T 细胞功能异常。
Zotero 插件